Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published review analyses for the evaluation of reimbursement applications:
- Opdivo (nivolumab) in the treatment of patients with urothelial cancer
- Truqap (capivasertib) in the treatment of breast cancer patients
- Balversa (erdafitinib) in the treatment of patients with urothelial cancer
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
